Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 14/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | ALPL | P05186 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30075985 | 0.93 | ATF4 (0.53) | ATF4MEN1KMT2APOLBABL1 | |
| SCHEMBL20973915 | 0.93 | ATF4 (0.53) | ATF4MEN1KMT2APOLBABL1 | |
| SCHEMBL20974079 | 0.89 | ATF4 (0.49) | ATF4MEN1KMT2APOLBABL1 | |
| SCHEMBL30025244 | 0.83 | ATF4 (0.44) | ATF4MEN1KMT2APOLBABL1 | |
| SCHEMBL19555456 | 0.83 | ATF4 (0.63) | ATF4 | |
| SCHEMBL30024691 | 0.83 | ATF4 (0.63) | ATF4 | |
| SCHEMBL19555320 | 0.80 | ATF4 (0.59) | ATF4 | |
| SCHEMBL30025967 | 0.80 | ATF4 (0.59) | ATF4 | |
| SCHEMBL22669493 | 0.78 | MEN1 (0.42) | ATF4MEN1KMT2APOLBABL1 | |
| SCHEMBL19555482 | 0.78 | ATF4 (0.51) | ATF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704094-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4356971-A2 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2024-04-24 | — | — | EP | disclosed |
| CN-115947681-A | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2023-04-11 | — | — | CN | disclosed |
| US-20220363678-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2022-11-17 | — | — | US | disclosed |
| CN-109641844-B | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2022-11-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363678-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ATF4 1/4885MEN1 4714/4885KMT2A 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.